Background We performed a retrospective chart review on COVID-19 patients treated at Arrowhead Regional Medical Center (ARMC) in Colton, California from January through October 2020. Two outcomes were measured: time to recovery and mortality outcome. Models were subsequently generated to investigate the role of remdesivir on these patient outcomes. Methods This study compares data on the Top 20 MSAs with the highest cumulative COVID-19 case rate at two timepoints (October 13, 2020 and January 1, 2021). The means of CDC’s Social Vulnerability Index (SVI) variables for the highest risk MSAs were compared with the Welch Two Sample t-test to the means of the SVI variables for the rest of the U.S. Results While initial research indicated that remdesivir decreased time to recovery, we found no such appreciable decrease in our study population. Our data corroborates existing studies on the lack of remdesivir’s impact on mortality. When controlling for days from symptom onset to administration of this medication, these outcomes do not change. Conclusion Our data demonstrate that remdesivir does not significantly alter time to recovery or mortality in COVID-19 patients. While the National Institute of Health (NIH) has sanctioned remdesivir’s use for certain COVID-19 populations, we do not observe any appreciable effects of this implementation at our county hospital. Increasing sample size and investigating inclusion criteria may help elucidate this observed lack of effect.